Isaacs Named Chief Medical Officer of Entasis Therapeutics.
- US-based antibacterial drug developer Entasis Therapeutics has appointed Robin David Isaacs, M.D., as chief medical officer, the company said on Wednesday.
Isaacs has experience as a pharmaceutical executive in the development and launch of vaccine and infectious disease products.
He has held positions of increasing responsibility at Merck and Co., Inc. Most recently, he held the title of vice president and therapeutic area head, vaccine clinical research.
During his 18 years at Merck, Isaacs was involved with the worldwide development, regulatory submission, and approval of many anti-infective, antiviral, and vaccine products.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections.
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Jul 15, 2015|
|Previous Article:||Geneuity to Expand Pharmaceutical Services Using Thermo Fisher's Oncomine Assay.|
|Next Article:||Diagnostics Company Theranos Teams with AmeriHealth Caritas.|